Gastroparesis Treatment Market Players, Drivers, Size, Share, Growth and Opportunities by 2032

Comments · 426 Views

The Gastroparesis Treatment Market is anticipated to reach USD 8.27 Billion by 2032 at 3.2% CAGR during the forecast period 2023-2032

Gastroparesis Treatment Market Highlights

The drugs product type segment is expected to account for the maximum market share of the global Gastroparesis treatment market. Prokinetic medications that stimulate gastric emptying, including metoclopramide, erythromycin, and domperidone, lead the drug segment. Although Idiopathic Gastroparesis leads the market share the Diabetic Gastroparesis is the fastest growing segment. Gastric electric stimulation (GES) etc. will however grow at a faster level as compared to drug segment.


The Gastroparesis Treatment Market is anticipated to reach USD 8.27 Billion by 2032 at 3.2% CAGR during the forecast period 2023-2032

Gastroparesis is a chronic digestive disorder characterized by delayed stomach emptying, leading to a range of symptoms such as nausea, vomiting, abdominal pain, and a feeling of fullness. This condition poses a significant challenge to patients' quality of life. In recent years, the gastroparesis treatment market has witnessed substantial growth, driven by advances in medical research, innovative therapies, and a growing awareness of the condition. This article delves into the evolving landscape of the gastroparesis treatment market, highlighting key trends, challenges, and promising developments.

The product development strategy is the best when it comes to be the market leader. There is a need of novel drug with greater efficacy and low side effects. The device segment is the segment to watch as there will be greater growth and has a high potential for product development such as miniaturization.

Latest developments include the ability to activate and program the device externally. Another development is connecting the link with mobile apps to have a detailed record and analysis of the working of the device. Jejunostomy leads the surgery treatment which involves bypassing the gastric area to speed up the passage of food.

Regional Analysis:

Depending on geographic region, new gastroparesis medication 2020 is segmented into four key regions: America, Europe, Asia Pacific, and Middle East Africa. Globally, America is the largest market for Gastroparesis Treatment as there is a consistent technological advancement and good reimbursement scenario. Europe is the second-largest market for Gastroparesis Treatment. Asia Pacific region is expected to generate fastest growth due to larger population and unmet needs.               


Global Gastroparesis Treatment market outlook has been segmented on the basis of Gastroparesis type which comprises idiopathic, diabetic, post-surgical and others.

On the basis of drug class the market comprises of prokinetic drugs, antiemetics, antidepressants and others.

On the basis of other treatment, market is segmented into jejunostomy, gastric electric stimulation (GES) and parenteral nutrition.

Key Players:

The major participants of this market are Medtronic, Kimberly-Clark Corporation, Abbott Laboratories, Salix Pharmaceuticals, Inc., Boston Scientific Corporation, C. R. Bard, Inc., Janssen Global Services, LLC, Cardinal Health, Inc., Alfa Wassermann SPA, Evoke Pharma, Rhythm Pharmaceuticals, Inc. and others.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071